Minthon, Lennart

A Selected Reaction Monitoring (SRM)-Based Method for Absolute Quantification of Aβ 38 , Aβ 40 , and Aβ 42 in Cerebrospinal Fluid of Alzheimer's Disease Patients and Healthy Controls

Pannee, J., Portelius, E., Oppermann, M., Atkins, A., Hornshaw, M., Zegers, I., Höjrup, P., Minthon, L., Hansson, O., Zetterberg, H., et al. (2013) · Journal of Alzheimer’s Disease

Alzheimer's disease research and treatmentsAdvanced Proteomics Techniques and Applications

Cited by 105

Altered CSF Orexin and α-Synuclein Levels in Dementia Patients

Wennström, M., Londos, E., Minthon, L., & Nielsen, H. M. (2012) · Journal of Alzheimer's Disease

Sleep and Wakefulness ResearchAlzheimer's disease research and treatments

Cited by 104

An Integrated Workflow for Multiplex CSF Proteomics and Peptidomics—Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease

Hölttä, M., Minthon, L., Hansson, O., Holmén-Larsson, J., Pike, I., Ward, M., Kuhn, K., Rüetschi, U., Zetterberg, H., Blennow, K., et al. (2015) · Journal of Proteome Research

Advanced Proteomics Techniques and ApplicationsAlzheimer's disease research and treatments

Cited by 100

Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment

Clerx, L., van Rossum, I. A., Burns, L., Knol, D. L., Scheltens, P., Verhey, F., Aalten, P., Lapuerta, P., van de Pol, L., van Schijndel, R., et al. (2013) · Neurobiology of Aging

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 98

Low IL ‐8 is associated with anxiety in suicidal patients: genetic variation and decreased protein levels

Janelidze, S., Suchankova, P., Ekman, A., Erhardt, S., Sellgren, C., Samuelsson, M., Westrin, A., Minthon, L., Hansson, O., Träskman‐Bendz, L., et al. (2015) · Acta Psychiatrica Scandinavica

Suicide and Self-Harm StudiesTryptophan and brain disorders

Cited by 86

Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting

Wallin, Å. K., Andreasen, N., Eriksson, S., Båtsman, S., Näsman, B., Ekdahl, A., Kilander, L., Grut, M., Rydén, M., Wallin, A., et al. (2007) · Dementia and Geriatric Cognitive Disorders

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 84

Mild versus moderate stages of Alzheimer’s disease: Three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy

Wattmo, C., Minthon, L., & Wallin, Å. K. (2016) · Alzheimer's Research & Therapy

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 83

Soluble adhesion molecules and angiotensin-converting enzyme in dementia

Nielsen, H. M., Londos, E., Minthon, L., & Janciauskiene, S. M. (2007) · Neurobiology of Disease

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 80

Processing of neuropeptide Y, galanin, and somatostatin in the cerebrospinal fluid of patients with Alzheimer’s disease and frontotemporal dementia

Nilsson, C. L., Brinkmalm, A., Minthon, L., Blennow, K., & Ekman, R. (2001) · Peptides

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 79

Genome-wide, high-content siRNA screening identifies the Alzheimer’s genetic risk factor FERMT2 as a major modulator of APP metabolism

ADGC, A. D. N. I., Chapuis, J., Flaig, A., Grenier-Boley, B., Eysert, F., Pottiez, V., Deloison, G., Vandeputte, A., Ayral, A.-M., Mendes, T., et al. (2017) · Acta Neuropathologica

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 75

NG2 cells, a new trail for Alzheimer’s disease mechanisms?

Nielsen, H. M., Ek, D., Avdic, U., Orbjörn, C., Hansson, O., Bank, T. N. B., Veerhuis, R., Rozemuller, A. J., Brun, A., Minthon, L., et al. (2013) · Acta Neuropathologica Communications

Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 71

Altered Chemokine Levels in the Cerebrospinal Fluid and Plasma of Suicide Attempters

Janelidze, S., Ventorp, F., Erhardt, S., Hansson, O., Minthon, L., Flax, J., Samuelsson, M., Traskman-Bendz, L., & Brundin, L. (2013) · Psychoneuroendocrinology

Tryptophan and brain disordersSuicide and Self-Harm Studies

Cited by 69

Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET

van Westen, D., Lindqvist, D., Blennow, K., Minthon, L., Nägga, K., Stomrud, E., Zetterberg, H., & Hansson, O. (2016) · Scientific Reports

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 66

CSF amyloid 38 as a novel diagnostic marker for dementia with Lewy bodies

Mulugeta, E., Londos, E., Ballard, C., Alves, G., Zetterberg, H., Blennow, K., Skogseth, R., Minthon, L., & Aarsland, D. (2011) · Journal of Neurology, Neurosurgery & Psychiatry

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 54

Single-Domain Amnestic Mild Cognitive Impairment Identified by Cluster Analysis Predicts Alzheimer's Disease in the European Prospective DESCRIPA Study

Damian, M., Hausner, L., Jekel, K., Richter, M., Froelich, L., Almkvist, O., Boada, M., Bullock, R., De Deyn, P. P., Frisoni, G. B., et al. (2013) · Dementia and Geriatric Cognitive Disorders

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 53

Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment

Wattmo, C., Wallin, Å. K., Londos, E., & Minthon, L. (2011) · Alzheimer Disease & Associated Disorders

Dementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

Cited by 52

Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy

Wallin, Å. K., Gustafson, L., Sjögren, M., Wattmo, C., & Minthon, L. (2004) · Dementia and Geriatric Cognitive Disorders

Dementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

Cited by 45

Cystatin C Levels are Positively Correlated with both Aβ42 and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls

Sundelöf, J., Sundström, J., Hansson, O., Eriksdotter-Jönhagen, M., Giedraitis, V., Larsson, A., Degerman-Gunnarsson, M., Ingelsson, M., Minthon, L., Blennow, K., et al. (2010) · Journal of Alzheimer's Disease

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 32

Increased frequency of a new polymorphism in the cell division cycle 2 (cdc2) gene in patients with Alzheimer's disease and frontotemporal dementia

Johansson, A., Hampel, H., Faltraco, F., Buerger, K., Minthon, L., Bogdanovic, N., Sjögren, M., Zetterberg, H., Forsell, L., Lilius, L., et al. (2003) · Neuroscience Letters

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 31

Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study

Chincarini, A., Bosco, P., Gemme, G., Esposito, M., Rei, L., Squarcia, S., Bellotti, R., Minthon, L., Frisoni, G., Scheltens, P., et al. (2014) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchMedical Image Segmentation Techniques

Cited by 22